Watch the video and download the slides
Hemato-oncology
New Molecular Approaches in DLBCL
Dr Brian T. Hill discusses New Molecular Approaches in Diffuse Large B-Cell Lymphoma (DLBCL)
Publication Date
Sep 2021
Dr Hill is the Director of the Lymphoid Malignancies Program and a Staff Physician in the Cleveland Clinic Taussig Cancer Institute. He received his undergraduate degree from Dartmouth College and earned his Ph.D. in genetics through work done at Cold Spring Harbor Laboratory. He received his medical degree from the University of Chicago Pritzker School of Medicine where he also completed his residency in Internal Medicine. He completed his hematology/oncology fellowship at the Cleveland Clinic. His clinical and research focus is in chronic lymphocytic leukemia (CLL) and lymphoma. He is the principal investigator of multiple on-going clinical trials of new cancer treatments including novel cellular therapies
Dr Brian Hill has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Abbvie, AstraZeneca, Genetech, Gilead and Pharmacyclics
DOWNLOAD THE SLIDES 
Programme summary
Duration 5 MIN- Downloadable resources Yes
-
DOWNLOAD THE SLIDES
HCPs enrolled 123 HCPs- Language(s)
Duration 
HCPs enrolled 
Language(s) 
Share this programme
Brought to you by
LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and from Karyopharm Therapeutics.
Meet the expertsOther programmes of interest
Conference update
Episode
1
of 6
Oncology Obstetrics and Gynecology Hemato-oncology
Listen to Expert Insights on Late-Breaking Data from ASCO 2023
Episode 1: Non-Small-Cell Lung Cancer Update: ADAURA trial
Experts
Dr Mansoor Raza Mirza, Dr Paolo Tarantino, Prof. Alexey V Danilov, Prof. Mark Socinski, Prof. Evan Yu, Prof. Thomas Powles, Assoc. Prof. Gerald Prager-
2 MIN
-
Jun 2023
2 MIN
Jun 2023 
Oncology Hemostasis and bleeding disorders Hemato-oncology
Update From ASH 2022
Highlights from the ASH Annual Meeting
Experts
Dr Matthew J. Matasar-
4 MIN
-
Dec 2022
Hemato-oncology
Update from ASCO 2022 – Myeloma
Dr Hans Lee summarises the highlights from the phase 3 DETERMINATION trial: Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM)
Experts
Asst. Prof. Hans Lee-
2 MIN
-
May 2022
Podcast
Episode
3
of 3
Hemato-oncology
Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics
Episode 3: Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics
Experts
Assoc. Prof. María Victoria Mateos, Dr Alexander M Lesokhin-
Downloadable
Resouces -
20 MIN
-
Mar 2022
Downloadable
Hemato-oncology
Lymphoma Update from ASH 2021
Dr. Matthew J. Matasar summarises the highlights in lymphoma from ASH 2021, including POLARIX, CAR-T in LBCL and mosunetuzumab in FL
Experts
Dr Matthew J. Matasar-
Downloadable
Resouces -
5 MIN
-
Dec 2021
Hemato-oncology
DLBCL Review Paper Published in The Oncologist
Authored by LYMPHOMA & MYELOMA CONNECT members, the paper ‘Translating the Biology of Diffuse Large B-cell Lymphoma into Treatment’ provides an overview of recent advances in DLBCL biology and how they can be translated into clinical care.
Experts
Dr Matthew J. Matasar, Dr Massimo Magagnoli, Prof. Alexey V Danilov-
Downloadable
Resouces -
5 MIN
-
Nov 2021